Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
47 results about "Muscle dystrophy" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Automated therapy table for treating lower extremities and method therefor
An automated therapy table is disclosed. The automated therapy table may have various support portions capable of independent automatic actuation of a person's lower extremities through passive exercise. The automated therapy table allows a patient to perform leg elevation, approximation / decompression of the leg, internal / external rotation of the leg, ankle plantar flexion / dorsiflexion, and foot inversion / eversion movements. During each movement, the patient may be instructed to think in the direction of the movement. It has been found that doing so helps increase the healing effects. The disclosed table and method may be beneficial for patients after certain operations as well as for those suffering from various forms of debilitating illnesses, such as Multiple Sclerosis, Charcot-Marie-Tooth, and Muscular Dystrophy.
Owner:SCHAEFFER DWIGHT L
Polymorphs of an androgen receptor modulator
InactiveUS20070129548A1Maintain good propertiesEasy to processOrganic active ingredientsSkeletal disorderDiseaseAging skins
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
Owner:MERCK SHARP & DOHME CORP
17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and / or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive impairment, decreased libido, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
Owner:MERCK SHARP & DOHME CORP
Automated therapy table for treating lower extremities and method therefor
An automated therapy table is disclosed. The automated therapy table may have various support portions capable of independent automatic actuation of a person's lower extremities through passive exercise. The automated therapy table allows a patient to perform leg elevation, approximation / decompression of the leg, internal / external rotation of the leg, ankle plantar flexion / dorsiflexion, and foot inversion / eversion movements. During each movement, the patient may be instructed to think in the direction of the movement. It has been found that doing so helps increase the healing effects. The disclosed table and method may be beneficial for patients after certain operations as well as for those suffering from various forms of debilitating illnesses, such as Multiple Sclerosis, Charcot-Marie-Tooth, and Muscular Dystrophy.
Owner:SCHAEFFER DWIGHT L
Fluorinated 4-azasteroid derivatives as androgen receptor modulators
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and / or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
Owner:MERCK SHARP & DOHME CORP
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
Owner:MERCK SHARP & DOHME CORP
17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
Owner:MERCK SHARP & DOHME CORP
Treatment of muscular dystrophies and associated conditions by administration of monoamine oxidase inhibitors
ActiveUS20120329800A1Reduce and prevent productionImproving MDBiocideOrganic chemistryDuchenne muscular dystrophyMuscular dystrophy
Administration of a monoamine oxidase inhibitor is useful in the prevention and treatment of muscle dystrophy. Methods and compositions for inhibiting the production of reactive oxygen species in a muscle cell overproducing reactive oxygen species are provided herein.
Owner:UNIV DEGLI STUDI DI PADOVA
Injection composition containing coenzyme Q10 and preparation method of injection composition
InactiveCN106377497AActive cooperationOrganic active ingredientsSenses disorderNeuropathic bladderSolvent
The invention discloses an injection composition containing coenzyme Q10 and a preparation method of the injection composition. The injection composition containing the coenzyme Q10 is prepared from the following raw materials in parts by weight: 1 to 10 parts of the reduced coenzyme Q10, 5 to 15 parts of glycerinum, 5 to 15 parts of hydroxypropyl methyl cellulose, 5 to 15 parts of a cosolvent, 0.2 to 2 parts of a stabilizer and 65 to 85 parts of water. According to the injection composition containing the coenzyme Q10, disclosed by the invention, regenerated energy can be injected into skin directly, the injection composition is resistant to oxidation, and the injection composition has active synergism on esophageal tube perfusion therapy for muscular dystrophy, hearing disturbance, neurogenic cystitis, cardiac valve replacement, coronary artery bypass graft, heart transplantation and the like.
Owner:温迪熊(上海)儿童用品股份有限公司
Polymorphs of an androgen receptor modulator
InactiveUS7365202B2Maintain good propertiesEasy to processOrganic active ingredientsSkeletal disorderDiseaseAging skins
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
Owner:MERCK SHARP & DOHME CORP
Surface expression vector for fusion protein of Myo-2 peptide multimer and myostatin, and microorganism transformed by thereof
The present invention relates to a fusion protein in which a myostatin mature protein is fused to a multimer of myostatin-derived antigenic peptide Myo-2, a surface expression vector containing a polynucleotide encoding the fusion protein, a recombinant microorganism transformed with the vector, and a feedstuff additive or a pharmaceutical composition containing the microorganism as an effective ingredient. The feedstuff additive or pharmaceutical composition according to the present invention can be used for muscle development and regulation of muscle growth in livestock and poultry, as wellas for preventing and treating muscle- wasting diseases and degenerative diseases such as muscular dystrophy, muscular atrophy and the like. In addition, the transformed strain shows the same effect even if the strain itself after culture thereof is directly used, and thus it is very economical.
Owner:BIOLEADERS CORP +2
Agents for preventing and treating disorders involving modulation of the RyR receptors
ActiveUS8022058B2Organic active ingredientsBiocideVentricular dysrhythmiaSIDS - Sudden infant death syndrome
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Treatment of Muscular Conditions and Muscular Dystrophies
InactiveUS20140256644A1Reduced mechanical propertiesDecreasing cytoskeletal stiffnessBiocidePeptide/protein ingredientsDiseaseMuscular dystrophy
The present invention provides methods for improving muscular function or treating a muscular disorder in an individual by administering to the individual a pharmacologically effective amount of a compound that inhibits microtubule-dependent NADPH Oxidase 2 reactive oxygen species signaling production. In addition compounds that block sarcolemmal Ca2+ channel activation and / or renin-angiotensin signaling may be administered with the inhibitor of microtubule-dependent NADPH Oxidase 2 reactive oxygen species signaling production.
Owner:UNIV OF MARYLAND BALTIMORE
N-(Pyridin-3-Yl)-2-Phenylbutanamides As Androgen Receptor Modulators
InactiveUS20080124402A1Minimal effectReduce decreaseOrganic active ingredientsPeptide/protein ingredientsDiseaseAging skins
Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
Owner:MERCK SHARP & DOHME CORP
17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
InactiveCN1849126AReduce consumptionIncrease the number ofNervous disorderAntipyreticDiseaseHormone Receptor Modulators
Compounds of formula I are modulators of the androgen receptor (AR) acting in a tissue-selective manner. These compounds alone or in combination with other active agents are effective in enhancing debilitating muscle tone and treating conditions caused by androgen deficiency or ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced bone Osteoporosis, periodontal disease, fractures, bone damage after bone reconstruction surgery, sarcopenia, frailty, aging skin, hypogonadism in men, postmenopausal syndrome in women, atherosclerosis, hypercholesterolemia, hyperlipidemia obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hypertrophy (BPH), abdominal obesity, metabolic syndrome, type II diabetes, cancer cachexia, al Alzheimer's disease, muscular dystrophy, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure and autoimmune diseases.
Owner:MERCK & CO INC
Methods and compositions for treating muscle disease and disorders
ActiveUS20180333467A1Improve heart functionAvoid delayPeptide/protein ingredientsInorganic non-active ingredientsDiseaseMyopathy
The present disclosure provides a method of treating muscle myopathy, including muscle dystrophies and cardiomyopathies, by administering stable, long-lasting vasoactive intestinal peptide therapeutic agents. These agents include one or more elastin-like peptides and can be administered at a low-dose.
Owner:PHASEBIO PHARMA INC
Treatment of muscular dystrophies and associated conditions by administration of monoamine oxidase inhibitors
Owner:UNIV DEGLI STUDI DI PADOVA
Modified U7 snRNAs for treatment of neuromuscular diseases
ActiveUS9080170B2Inefficient sequencingSplicing alterationNervous disorderDiseaseNeuromuscular disease
The present invention relates to a method to improve the activity of engineered U7 snRNAs used in the context of RNA-based therapeutics; particularly in exon skipping, exon inclusion, and mRNA eradication strategies. The resulting modified U7 snRNAs are useful for treating neuromuscular diseases, in particular Duchenne neuromuscular dystrophy, myotonic dystrophy DM1 and spinal muscular atrophy.
Owner:ASSOC INST DE MYOLOGIE +3
N-(Pyridin-4-Yl)-2-Phenylbutanamides as Androgen Receptor Modulators
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
Owner:MERCK SHARP & DOHME CORP
Methods, compounds, and compositions for the treatment of musculoskeletal diseases
This invention provides methods, compounds and compositions for the treatment of musculoskeletal disease, muscle dysfunction, muscle-wasting disease or disorder, including hereditary myopathy, neuromuscular disease, muscular dystrophy, muscular atrophy, drug-induced myopathy, and related disease, disorder or condition that causes a decrease in muscle strength, comprising the use of heterocyclic non-peptidic compounds that act as Mas agonists and / or mimics of angiotensin 1-7.
Owner:UNIV OF SOUTHERN CALIFORNIA
Methods for treatment of muscular dystrophies
InactiveCN105979943AOrganic active ingredientsNervous disorderDuchenne muscular dystrophyMuscular dystrophy
The invention discloses methods for treatment of muscular dystrophies. The present invention relates to, inter alia, treatment of muscle dystrophy (e.g., Duchenne Muscular Dystrophy), for example, using a composition, e.g., a composition comprising Compound (I), or a pharmaceutically acceptable salt, prodrug or metabolite thereof.
Owner:厄恩斯特.D.布什 +9
Methods and compositions for treating muscle disease and disorders
ActiveUS10688156B2Improve heart functionAvoid delayPeptide/protein ingredientsAerosol deliveryDiseaseMyopathy
The present disclosure provides a method of treating muscle myopathy, including muscle dystrophies and cardiomyopathies, by administering stable, long-lasting vasoactive intestinal peptide therapeutic agents. These agents include one or more elastin-like peptides and can be administered at a low-dose.
Owner:PHASEBIO PHARMA INC
Treatment of muscular conditions and muscular dystrophies
The present invention provides methods for improving muscular function or treating a muscular disorder in an individual by administering to the individual a pharmacologically effective amount of a compound that inhibits microtubule-dependent NADPH Oxidase 2 reactive oxygen species signaling production. In addition compounds that block sarcolemmal Ca2+ channel activation and / or renin-angiotensin signaling may be administered with the inhibitor of microtubule-dependent NADPH Oxidase 2 reactive oxygen species signaling production.
Owner:UNIV OF MARYLAND BALTIMORE
Oligonucleotide compositions and methods of use thereof
Among other things, the present disclosure provides designed oligonucleotides, compositions, and methods of use thereof. In some embodiments, the present disclosure provides technologies useful for reducing levels of transcripts. In some embodiments, the present disclosure provides technologies useful for modulating transcript splicing. In some embodiments, provided technologies can alter splicingof a dystrophin (DMD) transcript. In some embodiments, the present disclosure provides methods for treating diseases, such as Duchenne muscular dystrophy, Becker's muscular dystrophy, etc.
Owner:WAVE LIFE SCI LTD
17-Acetamido-4-azasteroid derivatives as androgen receptor modulators
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
Owner:MERCK SHARP & DOHME CORP
Specific modulators of connexin hemichannels
The invention provides identification methods of specific modulators of hemichannels formed by connexin through the use of structural bioinformation methods for the calculation of the interaction energy with ligands and compositions to selectively modulate the activity of hemichannels formed by connexins.Among other aspects, the invention describes a computer-aided method, where estimating the interaction energy between ligands coming from a database of chemical compounds is possible, with a binding pocket defined by the region comprising the residues of 3-10 (NTH), 29-40 (TM1), 74-93 (TM2) of a protomer and residues 29-40 (TM1) of an adjacent protomer in connexin 26 or the equivalent residues in other connexins.In particular, the invention provides compounds specifically inhibiting the activation / opening of connexin hemichannels identified through the method described above, which can be useful for the treatment of inflammatory diseases, vascular disorders, arrhythmias, chronic injuries, retinal neuroprotection, treatment of pain, skeletal muscle denervation, muscular dystrophies, damage to the spinal cord and genetic diseases characterized by the increased activity of hemichannels formed by connexins.
Owner:PONTIFISIA UNIVERSIDAD KATOLIKA DE CHILE
Methods for treatment of muscular dystrophies
InactiveUS20160250188A1Reduce negative impactAction specificationOrganic active ingredientsNervous disorderMetaboliteMedicine
The present invention relates to, inter alia, treatment of muscle dystrophy (e.g., Duchenne Muscular Dystrophy), for example, using a composition, e.g., a composition comprising Compound (I), or a pharmaceutically acceptable salt, prodrug or metabolite thereof.
Owner:AKASHI THERAPEUTICS
P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
ActiveUS20190105311A1Reduce expressionLower Level RequirementsPowder deliverySpray deliveryKinaseMuscle dystrophy
The disclosure relates to methods and compositions including p38 kinase inhibitors and agents that regulate expression of DUX4 and downstream genes including but not restricted to ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDC1L, RFPL2, CCNA1, SLC34A2, TPRX1, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF15, or ZNF280A. Methods useful for treating a disease associated with abnormal DUX4 and downstream gene expression (e.g., Facioscapulohumeral muscular dystrophy) are disclosed.
Owner:FULCRUM THERAPEUTICS INC
Oligonucleotide compositions and methods of use thereof
Among other things, the present disclosure provides designed DMD oligonucleotides, compositions, and methods of use thereof. In some embodiments, the present disclosure provides technologies useful for repairing mutant DMD transcripts by skipping exon 51 or exon 53, so that the transcript can be translated into an internally truncated but at least partially functional Dystrophin protein variant. In some embodiments, the present disclosure provides technologies useful for modulating DMD transcript splicing. In some embodiments, provided technologies can alter splicing of a dystrophin (DMD)DMD transcript. In some embodiments, the present disclosure provides methods for treating diseases, such as muscular dystrophy, including but not limited to Duchenne muscular dystrophy, Becker's muscular dystrophy, etc.
Owner:WAVE LIFE SCI LTD
17-acetamido-4-azasteroid derivatives as androgen receptor modulators
Owner:MERCK SHARP & DOHME CORP
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com